GTBP · GT Biopharma, Inc. · Documents

GT Biopharma will ask stockholders on November 11, 2026 to eliminate obsolete preferred-stock charter provisions, increase authorized common stock from 25,000,000 to 250,000,000, approve issuance of 19.99% or more of outstanding shares, and authorize meeting adjournment.

GT Biopharma registers up to 13,502,835 common shares for selling-stockholder resale; it will receive no proceeds. The company also disclosed substantial doubt about its ability to continue as a going concern.

GT Biopharma seeks approval at its November 11, 2026 special meeting to increase authorized Common Stock from 25,000,000 to 250,000,000 and issue 19.99% or more of outstanding shares under the Securities Purchase Agreement. The Board recommends FOR each proposal.

GT Biopharma received Nasdaq notice on September 22, 2026 that its common stock regained compliance with the minimum bid price requirement after maintaining a closing bid price above $1.00 per share for at least ten consecutive business days.

GT Biopharma, Inc. amended its private placement on September 18, 2026, increasing preferred stock to 8,611.111 shares with aggregate stated value of $8,611,111.11 for $7,750,000, and increased designated Series M shares from 41,778 to 43,287.